FDA Seeks Sequencing Services for Evaluation of Viral Vaccine QC Technology
June 01, 2010
FDA Seeks Sequencing Services for Evaluation of Viral Vaccine QC Technology
The agency is requesting sequencing services on both the 454 and Illumina platforms. Beckman Coulter and Macrogen are among the companies interested in submitting proposals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Beckman Coulter Partners with Vitrology to Combine Sequencing and Biologics Safety Testing
January 25, 2011 / In Sequence - FDA Considers Sequencing for Quality-Control Testing of Vaccines
May 11, 2010 / In Sequence - Surprise Finding Points to Next-Gen Sequencing's Utility for Vaccine Quality Control
April 6, 2010 / In Sequence - Consortium Sequences Gut Microbiomes for 124 People on Illumina GA
March 9, 2010 / In Sequence - ABRF to Present Sequencing Platform Performance Study Next Week
March 13, 2012 / In Sequence